A detailed history of M28 Capital Management LP transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, M28 Capital Management LP holds 6,164,548 shares of WVE stock, worth $83.3 Million. This represents 48.05% of its overall portfolio holdings.

Number of Shares
6,164,548
Previous 6,164,548 -0.0%
Holding current value
$83.3 Million
Previous $30.8 Million 64.33%
% of portfolio
48.05%
Previous 35.47%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$4.38 - $6.48 $3.66 Million - $5.41 Million
-835,452 Reduced 11.94%
6,164,548 $30.8 Million
Q1 2024

May 14, 2024

SELL
$3.54 - $6.84 $1.32 Million - $2.55 Million
-373,413 Reduced 5.06%
7,000,000 $43.2 Million
Q4 2023

Feb 12, 2024

BUY
$4.16 - $6.87 $1.37 Million - $2.26 Million
328,913 Added 4.67%
7,373,413 $37.2 Million
Q3 2023

Nov 13, 2023

SELL
$3.56 - $5.75 $19,580 - $31,625
-5,500 Reduced 0.08%
7,044,500 $40.5 Million
Q2 2023

Aug 11, 2023

BUY
$3.51 - $4.69 $351,000 - $469,000
100,000 Added 1.44%
7,050,000 $25.7 Million
Q1 2023

May 12, 2023

BUY
$3.58 - $6.3 $3.75 Million - $6.59 Million
1,046,595 Added 17.73%
6,950,000 $30.1 Million
Q4 2022

Feb 10, 2023

SELL
$3.18 - $7.0 $6.61 Million - $14.6 Million
-2,078,799 Reduced 26.04%
5,903,405 $41.3 Million
Q3 2022

Nov 10, 2022

SELL
$2.37 - $4.28 $711,000 - $1.28 Million
-300,000 Reduced 3.62%
7,982,204 $28.8 Million
Q2 2022

Aug 12, 2022

BUY
$1.23 - $3.25 $2.99 Million - $7.9 Million
2,432,204 Added 41.58%
8,282,204 $26.9 Million
Q1 2022

May 13, 2022

BUY
$2.0 - $3.28 $4.17 Million - $6.84 Million
2,084,412 Added 55.35%
5,850,000 $11.7 Million
Q4 2021

Feb 11, 2022

BUY
$3.14 - $5.15 $11.8 Million - $19.4 Million
3,765,588 New
3,765,588 $11.8 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.17B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track M28 Capital Management LP Portfolio

Follow M28 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M28 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on M28 Capital Management LP with notifications on news.